Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Ulaner

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2016
Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast CancersGary A Ulaner, Debra A Goldman, Mithat Gönen, et al.
Blood Reviews|August 11, 2020
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarityBenjamin T Diamond, Even Rustad, Kylee Maclachlan, et al.
Clinical Nuclear Medicine|April 30, 2020
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-upSonia Mahajan, Reiko Nakajima, Mariko Yabe, et al.
Theranostics|February 12, 2020
The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and <i>In vivo</i> Performance of <sup>89</sup>Zr-DFO-PertuzumabDelphine Vivier, Kimberly Fung, Cindy Rodriguez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2014
Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 yearsChristopher C Riedl, Elina Slobod, Maxine Jochelson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2016
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCISTKatja Pinker, Christopher C Riedl, Leonard Ong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 4, 2026
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETsGeorge Sgouros, Gary A Ulaner, Bin He, et al.
Cancer Genetics and Cytogenetics|May 4, 2004
Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumorsXiaoming Yao, Ji-Fan Hu, Tao Li, et al.
AJR. American Journal of Roentgenology|December 20, 2023
<sup>18</sup>F-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies-<i>AJR</i> Expert Panel Narrative ReviewMatthew F Covington, Sophia R O'Brien, Courtney Lawhn-Heath, et al.
Radiology. Imaging Cancer|May 2, 2025
Evaluating Automated Tools for Lesion Detection on <sup>18</sup>F Fluoroestradiol PET/CT Images and Assessment of Concordance with Standard-of-Care Imaging in Metastatic Breast CancerRenee Miller, Mark Battle, Kristen Wangerin, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2016
Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast CancersGary A Ulaner, Debra A Goldman, Mithat Gönen, et al.
Blood Reviews|August 11, 2020
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarityBenjamin T Diamond, Even Rustad, Kylee Maclachlan, et al.
Clinical Nuclear Medicine|April 30, 2020
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-upSonia Mahajan, Reiko Nakajima, Mariko Yabe, et al.
Theranostics|February 12, 2020
The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and <i>In vivo</i> Performance of <sup>89</sup>Zr-DFO-PertuzumabDelphine Vivier, Kimberly Fung, Cindy Rodriguez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 13, 2014
Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 yearsChristopher C Riedl, Elina Slobod, Maxine Jochelson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2016
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCISTKatja Pinker, Christopher C Riedl, Leonard Ong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 4, 2026
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETsGeorge Sgouros, Gary A Ulaner, Bin He, et al.
Cancer Genetics and Cytogenetics|May 4, 2004
Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumorsXiaoming Yao, Ji-Fan Hu, Tao Li, et al.
AJR. American Journal of Roentgenology|December 20, 2023
<sup>18</sup>F-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies-<i>AJR</i> Expert Panel Narrative ReviewMatthew F Covington, Sophia R O'Brien, Courtney Lawhn-Heath, et al.
Radiology. Imaging Cancer|May 2, 2025
Evaluating Automated Tools for Lesion Detection on <sup>18</sup>F Fluoroestradiol PET/CT Images and Assessment of Concordance with Standard-of-Care Imaging in Metastatic Breast CancerRenee Miller, Mark Battle, Kristen Wangerin, et al.
Pageof 16